Ma Wei, Kang Yanhong, Ning Lanlan, Tan Jie, Wang Hanping, Ying Yi
Department of Respiration, Guangzhou First People's Hospital, Guangzhou, Guangdong 510180, P.R. China.
Department of Respiration, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510000, P.R. China.
Exp Ther Med. 2017 Oct;14(4):2853-2862. doi: 10.3892/etm.2017.4847. Epub 2017 Jul 28.
Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. In the current study, the insulin-like growth factor 1 receptor (IGF-1R) gene in the gefitinib-resistant human lung adenocarcinoma epithelial cell line A549 (A549/GR) was silenced using small interfering RNA (siRNA) in order to determine the role of microRNA (miRNA) in the development of resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. The relative gefitinib-resistant capacity in A549 and A549/GR cells was determined using a cell counting kit 8. A549/GR cells were transfected with chemically synthesized siRNA to silence the IGF-1R gene. A total of 48 h after siRNA transfection, IGF-1R expression in A549/GR cells was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. miRNA expression in A549/GR cells and A549/GR cells with silenced IGF-1R was analyzed using a miRNA microarray. The microarray results of 10 miRNAs were then compared with the results of RT-qPCR. The results demonstrated that the gefitinib-resistance capacity of A549/GR cells was six times higher than that of A549 cells. Additionally, RT-qPCR and western blotting demonstrated that the IGF-1R gene in A549/GR cells was successfully silenced by siRNA. The highest silencing rate (72%) of the IGF-1R gene was obtained using siRNA-2. The microarray identified 72 miRNAs with significantly different expression in A549/GR cells with silenced IGF-1R compared with A549/GR cells. Of the 72 differentially expressed miRNAs, 13 miRNAs (including miR-497-3p and miR-1273c) were up-regulated and 59 miRNAs (including miR-361-3p and miR-345-3p) were down-regulated in A549/GR cells with silenced IGF-1R compared with A549/GR cells. The changes in the expression of 10 different miRNAs were confirmed by RT-qPCR. Thus, the present study successfully established an A549/GR cell line with silenced IGF-1R. The results suggest that a number of miRNAs associated with the IGF-1R signaling pathway, including miR-497-3p and miR-144-5p, were involved in the development of resistance against EGFR-TKIs in A549 cells. These miRNAs may provide novel targets to treat lung adenocarcinoma exhibiting resistance against EGFR-TKIs.
多项临床和实验研究表明,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)可能对治疗晚期非小细胞肺癌(NSCLC)有效,然而,NSCLC对EGFR-TKIs原发性耐药的分子基础仍不清楚。在本研究中,使用小干扰RNA(siRNA)沉默了吉非替尼耐药的人肺腺癌上皮细胞系A549(A549/GR)中的胰岛素样生长因子1受体(IGF-1R)基因,以确定微小RNA(miRNA)在肺腺癌对表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)耐药发展中的作用。使用细胞计数试剂盒8测定A549和A549/GR细胞中的相对吉非替尼耐药能力。用化学合成的siRNA转染A549/GR细胞以沉默IGF-1R基因。siRNA转染后共48小时,使用逆转录定量聚合酶链反应(RT-qPCR)和蛋白质印迹法评估A549/GR细胞中IGF-1R的表达。使用miRNA微阵列分析A549/GR细胞和IGF-1R沉默的A549/GR细胞中的miRNA表达。然后将10种miRNA的微阵列结果与RT-qPCR结果进行比较。结果表明,A549/GR细胞的吉非替尼耐药能力比A549细胞高6倍。此外,RT-qPCR和蛋白质印迹法表明,A549/GR细胞中的IGF-1R基因被siRNA成功沉默。使用siRNA-2获得了IGF-1R基因的最高沉默率(72%)。微阵列鉴定出72种miRNA在IGF-1R沉默的A549/GR细胞中与A549/GR细胞相比表达有显著差异。在这72种差异表达的miRNA中,与A549/GR细胞相比,13种miRNA(包括miR-497-3p和miR-1273c)在IGF-1R沉默的A549/GR细胞中上调,59种miRNA(包括miR-361-3p和miR-345-3p)下调。通过RT-qPCR证实了10种不同miRNA表达的变化。因此,本研究成功建立了IGF-1R沉默的A549/GR细胞系。结果表明,一些与IGF-1R信号通路相关的miRNA,包括miR-497-3p和miR-144-5p,参与了A549细胞对EGFR-TKIs耐药的发展。这些miRNA可能为治疗对EGFR-TKIs耐药的肺腺癌提供新的靶点。